UK Biotech Funding & Grants News
Funding and grants help life sciences organisations finance research, develop products and expand their operations. This news category follows announced financing events involving UK biotechnology, pharmaceutical, research and laboratory technology organisations, from emerging spin-outs to established businesses.
T-Therapeutics Raises $133m Series B for TCR Bispecific Programmes
T-Therapeutics has raised $133m in an oversubscribed Series B round led by Advent Life Sciences and British Business Bank, with Johnson & Johnson Innovation, Lilly, Samsara BioCapital and M Ventures joining as new investors. The Cambridge company will use the funds to take two TCR-CD3 bispecific programmes, one in oncology and one in autoimmune disease, into the clinic.
bit.bio Secures $25m Series D to Expand Human Cell Portfolio
Cambridge-based bit.bio has secured $25 million (approximately £19 million) in Series D funding, with backing reported from M&G Investments and Abcam founder Jonathan Milner. The company plans to expand its portfolio of human iPSC-derived cell models and improve access for researchers. It reported a 76% increase in paid vial volumes during 2026, alongside growth in orders and active customers.
Milner Researcher Wins Quantum Funding for Drug Target Discovery
Dr Namshik Han, Head of AI and Computational Research at the Milner Therapeutics Institute, has received a research funding award through the University of Cambridge’s IonQ Quantum Innovation Centre. His group plans to apply quantum computing methods to drug-target discovery and aims to select and test a candidate target in human cells by 2029. The institute did not disclose an award amount.
VasoDynamics Receives Innovate UK Grant Offer for Bradford Research
VasoDynamics has received an Innovate UK Accelerate Knowledge Transfer grant offer to support a collaboration with the University of Bradford. The project will generate additional safety data in mouse models for the company's topical formulations, which are being developed to reduce adverse effects of anticancer treatments. The offer supports planned preclinical work; the announcement does not state that grant funding has been paid or the project completed.
imphatec Closes Oversubscribed £1.5M Seed Round Led by SynBioVen
imphatec has closed an oversubscribed £1.5 million seed round led by SynBioVen with participation from angel investors. The funding will take its synthetic biology implant, a subcutaneous device that releases medication over the long term at a customisable dose for chronic conditions, from preclinical work towards human trials.